Growth control of multiple myeloma cells through inhibition of glycogen synthase kinase-3
- 1 January 2008
- journal article
- research article
- Published by Informa UK Limited in Leukemia & Lymphoma
- Vol. 49 (10), 1945-1953
- https://doi.org/10.1080/10428190802304966
Abstract
Anti-apoptotic pathways play a central role in the survival of multiple myeloma cells. The contribution of PI3-kinase and Akt kinase in mediating myeloma cell survival is well established although the role of glycogen synthase kinase-3 (GSK3) is less defined. In this study we determined the contribution of GSK3 in growth regulation of myeloma cells. We treated six different multiple myeloma cell lines with a Thiadiazolidinone (TDZD), a non-competitive inhibitor of GSK3 and determined its effects on proliferation and apoptosis. In addition we determined the activation of forkhead transcription factors (FOXO) in response to TDZD. TDZD inhibited proliferation and induced apoptosis of all myeloma cell lines. TDZD was also effective in inducing apoptosis of primary myeloma cells whereas CD34 positive normal hematopoietic cells were protected from apoptosis. Furthermore, TDZD-mediated inhibition of GSK3 resulted in dephosphorylation and activation of FOXO3a. In primary myeloma cells FOXO transcription factors were highly phosphorylated where as the levels of GSK3 phosphorylation was quite low. The levels of the pro-apoptotic proteins Fas lignad (FasL) and IκBα increased after treatment with TDZD in myeloma cell lines. These studies provide the basis for further testing of GSK3 inhibitors in the clinical setting.Keywords
This publication has 48 references indexed in Scilit:
- The role of Forkhead-box Class O (FoxO) transcription factors in cancer: A target for the management of cancerToxicology and Applied Pharmacology, 2007
- Understanding multiple myeloma pathogenesis in the bone marrow to identify new therapeutic targetsNature Reviews Cancer, 2007
- Reciprocal Targeting of Hath1 and β-Catenin by Wnt Glycogen Synthase Kinase 3β in Human Colon CancerGastroenterology, 2007
- MLN120B, a Novel IκB Kinase β Inhibitor, Blocks Multiple Myeloma Cell Growth In vitro and In vivoClinical Cancer Research, 2006
- IGF-1 receptor tyrosine kinase inhibition by the cyclolignan PPP induces G2/M-phase accumulation and apoptosis in multiple myeloma cellsBlood, 2006
- Valproic Acid Stimulates Proliferation and Self-renewal of Hematopoietic Stem CellsCancer Research, 2005
- Myeloma cell contamination of peripheral blood stem-cell grafts can predict the outcome in multiple myeloma patients after high-dose chemotherapy and autologous stem-cell transplantationZeitschrift für Krebsforschung und Klinische Onkologie, 2004
- AS602868, a pharmacological inhibitor of IKK2, reveals the apoptotic potential of TNF-α in Jurkat leukemic cellsOncogene, 2003
- Control of Cell Cycle Exit and Entry by Protein Kinase B-Regulated Forkhead Transcription FactorsMolecular and Cellular Biology, 2002
- IL-6 up-regulates Mcl-1 in human myeloma cells through JAK / STAT rather than Ras / MAP kinase pathwayEuropean Journal of Immunology, 1999